These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28574577)

  • 1. PCSK9 and infection: A potentially useful or dangerous association?
    Khademi F; Momtazi-Borojeni AA; Reiner Ž; Banach M; Al-Rasadi KA; Sahebkar A
    J Cell Physiol; 2018 Apr; 233(4):2920-2927. PubMed ID: 28574577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
    Norata GD; Tavori H; Pirillo A; Fazio S; Catapano AL
    Cardiovasc Res; 2016 Oct; 112(1):429-42. PubMed ID: 27496869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
    Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
    PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 targets important for lipid metabolism.
    Schulz R; Schlüter KD
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
    Chen B; Shi X; Cui Y; Hou A; Zhao P
    Curr Top Med Chem; 2019; 19(20):1790-1817. PubMed ID: 31400268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications.
    Seidah NG
    Curr Opin Lipidol; 2016 Jun; 27(3):274-81. PubMed ID: 27031271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
    Ferri N; Corsini A; Macchi C; Magni P; Ruscica M
    Transl Res; 2016 Jul; 173():19-29. PubMed ID: 26548330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9: from biology to clinical applications.
    Blanchard V; Khantalin I; Ramin-Mangata S; Chémello K; Nativel B; Lambert G
    Pathology; 2019 Feb; 51(2):177-183. PubMed ID: 30522786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of PCSK9 in lipid metabolism and atherosclerosis.
    Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
    Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives.
    Tsouka AN; Tellis CC; Tselepis AD
    Curr Pharm Des; 2018; 24(31):3622-3633. PubMed ID: 30317986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
    Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
    Hyrina A; Olmstead AD; Steven P; Krajden M; Tam E; Jean F
    EBioMedicine; 2017 Sep; 23():68-78. PubMed ID: 28864162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.